Prev Arrow Stocks

Moderna Inc. ($MRNA) Stock Forecast: Up 6.6% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Moderna Inc.?

A biotechnology company known for its innovative mRNA technology, particularly its COVID-19 vaccine, has been closely watched.

Why is Moderna Inc. going up?

MRNA stock is up 6.6% on Feb 14, 2025 17:52

  • The company reported a Q4 loss but exceeded revenue estimates, indicating strong financial performance.
  • Struggles with scaling down manufacturing and launching new products may have impacted its profitability.
  • Investors may be optimistic about the company's future prospects, especially with the potential of its bird flu vaccine candidates and ongoing COVID-19 vaccine sales.
  • The bullish movement in the company's stock could be a result of investors focusing on the positive revenue surprise and the long-term growth potential of its vaccine portfolio.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna ( MRNA ) Reports Q4 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 7.06% and 1.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2416004/moderna-mrna-reports-q4-loss-tops-revenue-estimates

0 Missing News Article Image Moderna  ( MRNA )  Reports Q4 Loss, Tops Revenue Estimates

Moderna beats on revenue but loses more than expected as it scales down manufacturing

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

https://www.cnbc.com/2025/02/14/moderna-mrna-q4-earnings-2024.html

1 Missing News Article Image Moderna beats on revenue but loses more than expected as it scales down manufacturing

Palo Alto Networks, Moderna And 3 Stocks To Watch Heading Into Friday - DraftKings ( NASDAQ:DKNG ) , Enbridge ( NYSE:ENB )

With U.S. stock futures trading slightly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Enbridge Inc. ENB to report quarterly earnings at 52 cents per share on revenue of $4.78 billion before the opening bell, according to ...

https://www.benzinga.com/news/earnings/25/02/43724517/palo-alto-networks-moderna-and-3-stocks-to-watch-heading-into-friday

2 News Article Image Palo Alto Networks, Moderna And 3 Stocks To Watch Heading Into Friday - DraftKings  ( NASDAQ:DKNG ) , Enbridge  ( NYSE:ENB )

Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Moderna ( NASDAQ:MRNA )

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025. Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period.

https://www.benzinga.com/25/02/43721679/moderna-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts

3 News Article Image Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Moderna  ( NASDAQ:MRNA )

Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch - Moderna ( NASDAQ:MRNA )

Analysts expect Moderna to report quarterly losses of $2.68 per share and revenue of $942.84 million. Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights. Moderna, Inc.

https://www.benzinga.com/general/health-care/25/02/43716942/moderna-q4-earnings-preview-covid-19-vaccine-sales-bird-flu-vaccine-candidates-on-watch

4 News Article Image Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch - Moderna  ( NASDAQ:MRNA )

Moderna Inc. Price History

30.00.2025 - MRNA Stock was down 6.2%

  • A recent revision of Moderna's stock by an analyst led to a bearish movement, with a lower price target and a shift from Buy to Neutral.
  • Despite market fluctuations, Moderna saw a slight increase in its stock, closing at $41.66, showing some resilience.
  • Observations on the options activity for Moderna revealed a mixture of bullish and bearish trades, with significant bullish moves from financial giants reflecting varied sentiments among traders.
  • Market volatility, possibly influenced by global health concerns such as the CDC-WHO split and the discovery of a rare bird flu strain, may have impacted Moderna's stock performance.

04.01.2025 - MRNA Stock was down 6.8%

  • Moderna's stock experienced a bearish trend today following an analyst's decision to downgrade the stock from Buy to Neutral and lower the price target. This downgrade, alongside reduced revenue expectations, likely impacted investor confidence negatively.
  • While some investors showed bullish sentiment through options trading, overall market sentiment appears to have been influenced by the pessimistic outlook presented by the analyst.
  • Noteworthy options trading activity, encompassing both bullish and bearish trades, suggests uncertainty and volatility surrounding Moderna's stock, potentially contributing to its decline.
  • Investor wariness regarding Moderna's future earnings, particularly in anticipation of the forthcoming quarterly results, is evident. This caution aligns with discussions on biotech stocks poised to surpass Q4 earnings estimates.

27.00.2025 - MRNA Stock was up 5.3%

  • Moderna secured a significant European contract for its COVID-19 vaccine, which likely boosted investor confidence in the company's revenue stream and growth prospects.
  • Positive comments by Oracle Chairman Larry Ellison regarding the role of artificial intelligence in cancer treatment may have also contributed to the bullish sentiment surrounding Moderna.
  • Additionally, the news about Moderna testing a norovirus vaccine in a phase three trial could have further fueled optimism among investors about the company's pipeline and potential for future success.
  • Overall, positive vaccine-related developments and optimistic market sentiment towards healthcare and biotechnology stocks likely drove Moderna's strong bullish movement today.

28.00.2025 - MRNA Stock was up 5.1%

  • Moderna's upward movement today may be linked to securing a significant multi-year contract to supply its COVID-19 vaccine to 17 European countries, potentially boosting its revenue streams and global presence.
  • Positive market sentiment could also be influenced by recent statements made by Oracle Chairman Larry Ellison regarding the role of artificial intelligence in revolutionizing cancer treatment, indirectly benefiting Moderna's biotech innovations.
  • Ongoing global health issues, such as the CDC-WHO split and the identification of a rare bird flu strain, might have emphasized the importance of vaccine research, highlighting Moderna's competitive position within the industry.
  • In conclusion, a series of positive developments related to Moderna's vaccine agreements, technological progress, and the overall healthcare landscape likely contributed to the stock's upward trend.

03.01.2025 - MRNA Stock was down 5.1%

  • Despite the general optimism towards Moderna, a recent downgrade from a prominent analyst at Goldman Sachs from Buy to Neutral, accompanied by a lower price target, led to a downward trend in the stock.
  • The bullish outlook from investors in options trading did not seem to outweigh the impact of the analyst's downgrade.
  • The contrast between the positive options activity and the analyst's downgrade potentially created uncertainty among investors, contributing to the decline in Moderna's stock price.

29.00.2025 - MRNA Stock was down 5.3%

  • Moderna's stock faced a downturn post a revision by an analyst at Goldman Sachs, who adjusted the rating from Buy to Neutral and significantly lowered the price target.
  • The rationale behind the downgrade was tied to anticipated product revenue falling at the lower end of guidance, sparking worries among investors about upcoming financial performance.
  • Despite market challenges, Moderna's stock concluded with a slight uptick, demonstrating resilience amidst negative sentiment stemming from the analyst's actions.
  • This occurrence underscores the sway that analyst evaluations and revenue projections hold over stock movements, particularly in the volatile biotech sphere where investor outlook can swiftly change based on perceived growth opportunities.

29.00.2025 - MRNA Stock was up 5.2%

  • The upswing in Moderna's stock price might be connected to the acquisition of a multi-year contract to provide its COVID-19 vaccine to 17 European nations. This development marks a significant achievement for the company, signaling a promising revenue outlook.
  • The market's favorable response could also be influenced by ongoing global health concerns, including the CDC's suspension of collaboration with the WHO and the detection of a rare bird flu strain in California. This underscores the ongoing necessity for effective vaccines.
  • Despite a slight market decline, Moderna's strength and upward trajectory indicate investor faith in the company's adeptness at navigating challenges and seizing opportunities in the healthcare industry.

24.00.2025 - MRNA Stock was up 8.7%

  • Moderna experienced a rise in its stock price due to a major contract to supply its COVID-19 vaccine to 17 European countries, which instilled confidence in investors regarding the company's revenue.
  • Investor optimism was further bolstered by positive remarks from Oracle Chairman Larry Ellison on the promising role of artificial intelligence in cancer treatment, shedding light on Moderna's forward-looking strategies in healthcare.
  • The company's ongoing phase three trial for a norovirus vaccine also contributed to the positive outlook for Moderna, displaying the diversity of its pipeline and potential for growth in various healthcare areas.

24.00.2025 - MRNA Stock was up 14.8%

  • Moderna's shares surged today following positive comments by Oracle Chairman Larry Ellison on the role of artificial intelligence in cancer treatment, boosting investor confidence in the company's innovative approach.
  • The ongoing development of a norovirus vaccine in a phase three trial by Moderna also contributed to the bullish sentiment, with potential positive results expected later this year.
  • Additionally, news of Moderna receiving a substantial funding of $590 million to develop a vaccine for the bird flu outbreak further fueled investor optimism, highlighting the company's versatility in addressing emerging health challenges.
  • Overall, Moderna's proactive stance in vaccine development for various diseases, coupled with external endorsements and financial support, likely propelled its stock to a strong bullish movement today.

14.01.2025 - MRNA Stock was up 6.6%

  • The company reported a Q4 loss but exceeded revenue estimates, indicating strong financial performance.
  • Struggles with scaling down manufacturing and launching new products may have impacted its profitability.
  • Investors may be optimistic about the company's future prospects, especially with the potential of its bird flu vaccine candidates and ongoing COVID-19 vaccine sales.
  • The bullish movement in the company's stock could be a result of investors focusing on the positive revenue surprise and the long-term growth potential of its vaccine portfolio.

14.01.2025 - MRNA Stock was up 7.1%

  • Moderna reported a mixed earnings result, surpassing revenue expectations while recording a larger loss than expected, which potentially caused initial uncertainty in the market.
  • The bullish movement in Moderna's stock is possibly due to the market's focus on the company's initiatives to optimize manufacturing processes and introduce new products, showcasing resilience and adaptability within a challenging environment.
  • Despite some investors taking a bearish stance in the options market initially, the overall positive sentiment regarding Moderna's future prospects and product pipeline likely eclipsed these short-term bearish signals.
  • Investors seem hopeful about Moderna's long-term outlook, particularly with ongoing advancements in vaccine technology, and the company's demonstrated ability to navigate through changing market conditions, contributing to the positive stock movement.

11.01.2025 - MRNA Stock was down 5.3%

  • Moderna (MRNA) experienced a bearish movement possibly due to profit-taking after recent surges in its stock price.
  • Despite expectations of beating earnings estimates, investors may have been cautious about the company's pipeline updates.
  • The focus on other biotech stocks reporting earnings this week may have shifted attention away from Moderna, leading to the bearish movement.
  • The overall market sentiment towards biotech stocks and the anticipation of earnings reports could have influenced Moderna's stock performance negatively today.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.